SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001305253-23-000003
Filing Date
2023-03-16
Accepted
2023-03-16 16:43:20
Documents
14
Period of Report
2023-03-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eigr-20230316.htm   iXBRL 8-K 29843
2 EX-99.1 eigr-2023_marchxexx991.htm EX-99.1 114367
6 imagea.jpg GRAPHIC 28424
  Complete submission text file 0001305253-23-000003.txt   321087

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT eigr-20230316.xsd EX-101.SCH 1902
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT eigr-20230316_lab.xml EX-101.LAB 23832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT eigr-20230316_pre.xml EX-101.PRE 12508
8 EXTRACTED XBRL INSTANCE DOCUMENT eigr-20230316_htm.xml XML 4101
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 23739448
SIC: 2836 Biological Products, (No Diagnostic Substances)